ライフサイエンスコーパス: eliglustat

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 g-term extension phase in which all received eliglustat.

2 spleen volume and randomized 1:1 to receive eliglustat (50 or 100 mg twice daily; n = 20) or placebo

3 ment would remain so after switching to oral eliglustat, a selective inhibitor of glucosylceramide sy

4 we randomly allocated 106 (66%) patients to eliglustat and 54 (34%) to imiglucerase.

5 stat), myocardial infarction (one patient on eliglustat), and psychotic disorder (one patient on imig

6 y lived in the United States when commercial eliglustat became available.

7 with Gaucher disease type 1, treatment with eliglustat compared with placebo for 9 months resulted i

8 e we report long-term safety and efficacy of eliglustat for 157 patients who received eliglustat in t

9 a are available for 46 patients who received eliglustat for 4 years.

10 y 27.77% (95% CI, -32.57% to -22.97%) in the eliglustat group (from 13.89 to 10.17 multiples of norma

11 97 (92%) of 106 patients in the eliglustat group had treatment-emergent adverse events,

12 One patient in the eliglustat group withdrew (non-treatment related); 39 of

13 of eliglustat for 157 patients who received eliglustat in the ENCORE trial; data are available for 4

14 Oral eliglustat maintained haematological and organ volume st

15 occurred due to palpitations (one patient on eliglustat), myocardial infarction (one patient on eligl

16 -generated centrally) to receive either oral eliglustat or imiglucerase infusions for 12 months.

17 Duration on eliglustat ranged from 2 to 5 years, depending on timing

18 The non-inferiority margin was 25% for eliglustat relative to imiglucerase, assessed in all pat

19 In the phase 3 Study of Eliglustat Tartrate (Genz-112638) in Patients With Gauch

20 ation, 84 (85%) of 99 patients who completed eliglustat treatment and 44 (94%) of 47 patients who com

21 yme Replacement Therapy (ENCORE), at 1 year, eliglustat was noninferior to imiglucerase enzyme therap

22 Eliglustat was well tolerated over 4 years; 4 (2.5%) pat

23 lts with Gaucher disease type 1 treated with eliglustat who remained in the ENCORE trial for up to 4

24 olute differences between groups all favored eliglustat, with a 1.22-g/dL increase in hemoglobin leve

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。